Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin

Antiviral Therapy

Volumn 14, Issue 4, 2009, Pages 501-511

  Martinot Peignoux, Michelle ^a   Maylin, Sarah ^a   Moucari, Rami ^a   Ripault, Marie Pierre ^a   Boyer, Nathalie ^a   Cardoso, Ana Carolina ^a   Giuily, Nathalie ^a   Castelnau, Corinne ^a   Pouteau, Michèle ^a   Stern, Christiane ^a   Aupérin, Anne ^b   Bedossa, Pierre ^a   Asselah, Tarik ^a   Marcellin, Patrick ^a  

^a BEAUJON HOSPITAL   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2B; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ARTICLE; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; FEMALE; HEPATITIS C; HUMAN; MALE; MIDDLE AGED; PREDICTION AND FORECASTING; TIME; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 68549115307     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Maylin S, Martinot-Peignoux M, Moucari M, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008;135:821-829.
2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
4. Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon alpha 2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 2004;140:346-355.
5. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: June 10-12, 2002. Hepatology 2002;36 Suppl 1: S3-S20.
6. Marcellin P, Pouteau M, Martinot-Peignoux M, et al. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology 1995;109:156-165.
7. Martinot-Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum HCV-RNA levels and HCV genotype are the main and independent prognostic factors of sustained response to alpha interferon therapy in chronic hepatitis C. Hepatology 1995;22:1050-1056.
8. Martinot-Peignoux M, Boyer N, Pouteau M, et al. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J Hepatol 1998;29:214-223.
9. Berg T, Sarrazin C, Herrmann E, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003;37:600-609.
10. Von Wagner M, Huber M, Berg T, et al. Peginterferon-α-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129:522-527.
11. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97-103.
12. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginteferon alpha-2a (40kd)/ribavirin. Hepatology 2006;43:954-960.
13. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virological response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-652.
14. Ferenci P, Fried M W, Shiffman ML, et al. Predicting SVR in chronic hepatitis C patients treated with peginterferon alpha 2a (40KD)/ribavirin. J Hepatol 2005;43:425-433.
15. Dalgard O, Bjoro K, Block-Hellum K, et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004;40:1260-1265.
16. Carlsson T, Reichard O, Norkrans G, et al. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response. J Viral Hepat 2005;12:473-480.
17. Mangia A, Santoro R, Minerva N, et al. Pegintefereron alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-2617.
18. Martinot-Peignoux M, Comanor L, Minor JM, et al. Accurate models predicting sustained response with pegylated interferon with ribavirin in patients with chronic hepatitis C. J Viral Hepat 2006;13:701-707.
19. Martinez-Bauer E, Crespo J, Romero-Gomez M, et al. Development and validation of two models for early predeiction of response to therapy in genotype 1 chronic hepatitis C. Hepatology 2006;43:72-80.
20. Sanchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon alpha 2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006;131:451-460.
21. Moucari R, Ripault MP, Oulès V, et al. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy. J Hepatol 2007;46:596-604.
22. Pisani G, Cristiano K, Wirz M, Bisso GM, Gentili G. Overestimation of the hepatitis C virus RNA content of reference preparations by the AMPLICOR HCV Monitor test, version 2.0. J Clin Microbiol 2002;40:4765-4767.
23. Morishima C, Chung M, Ng KW, Brambilla DJ, Gretch DR. Strengths and limitations of commercial tests for Hepatitis C virus RNA quantification. J Clin Microbiol 2004;42:421-425.
24. Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology 2007;46:22-31.
25. Sarrazin C, Teuber G, Kokka R, Rabenau H, Zeuzem S. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virological response according to polymerase chain reaction-based assays. Hepatology 2000;32:818-823.
26. Gerotto M, Dal Pero F, Bortoletto G, et al. Hepatitis C minimal residual viremia [MRV] detected by TMA at the end of pegylated-interferon plus ribavirin therapy predicts post-treatment relapse. J Hepatol 2006;44:83-87.
27. Elbeik T, Surtihadi J, Destree M, et al. Multicenter evaluation of the performance characteristics of the Bayer VERSANT HCV-RNA 3.0 assay [bDNA]. J Clin Microbiol 2004;42:563-569.
28. Comanor L, Anderson F, Ghany M, et al. Transcriptionmediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV-RNA at end of treatment. Am J Gastroenterol 2001;96:2968-2972.
29. Bouchardeau F, Cantaloube JF, Chevaliez S, et al. Improvement of hepatitis C virus [HCV] genotype determination with the new version of the INNO-LiPA HCV assay. J Clin Microbiol 2007;45:1140-1145.
30. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-293.
31. Morishima C, Morgan TR, Everhart JE, et al. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology 2006;44:360-367.
32. Berg T, Weich V, Teuber G, et al. Importance of minimal residual viremia for relapse prediction in HCV type 1 patients receiving standard or individualized treatment. Hepatology 2007;46 Suppl 1:317A.
33. Yu ML, Dai CY, Huang JF, et al. A randomized study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007;56:553-559.
34. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotypes 2 or 3. N Engl J Med 2007;357:124-134.
35. Dalgard O, Bjoro K, Ring-Larsen H, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008;47:35-42.
36. Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008;47:43-50.
37. Berg T, Von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon alfa-2a plus ribavirin. Gastroenterology 2006;130:1086-1097.
38. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa 2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008;135:451-458.
39. Marcellin P, Heathcote EJ, Craxi A. Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with 'accordion' regimen? J Hepatol 2007;47:580-587.
40. Saracco G, Olivero A, Ciancio A, et al. A randomized 4-arms multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy. Hepatology 2002;36:959-966.
41. Pearlman BL, Ehleben C, Saife S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology 2007;46:1688-1694.